Takeda Pharmaceutical (NYSE:TAK) Releases Earnings Results, Misses Estimates By $0.07 EPS

Takeda Pharmaceutical (NYSE:TAK) released its earnings results on Thursday. The company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.07), Zacks reports. The business had revenue of $7.76 billion during the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.73%.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

• Takeda delivered three Phase‑3 wins—oveporexin, rusfertide and zasocitinib—has filed NDAs for the first two, is preparing the zasocitinib filing for 2027, and expects these launches over the next 18 months to be major growth drivers.
• Management cut revenue guidance to a low single‑digit decline at CER due mainly to stronger‑than‑expected generic erosion of Vyvanse, which was the primary headwind to year‑to‑date revenue performance.
• Operational cost discipline and lower R&D/SG&A allowed Takeda to maintain full‑year guidance for core operating profit and core EPS, and to upgrade adjusted free cash flow despite the Vyvanse headwind.
• Entyvio showed strong Q3 growth and broader U.S. pen coverage (~80%), but its selection for IRA price negotiation introduces uncertainty around 2028 Medicare pricing and potential impact on long‑term peak sales.

Takeda Pharmaceutical Trading Up 0.2%

NYSE TAK traded up $0.04 during trading on Friday, hitting $17.21. 5,626,273 shares of the company’s stock traded hands, compared to its average volume of 3,160,032. The stock has a fifty day moving average of $15.41 and a two-hundred day moving average of $14.81. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.37 and a quick ratio of 0.76. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $17.25. The firm has a market cap of $54.76 billion, a P/E ratio of 71.71 and a beta of 0.03.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. increased its stake in shares of Takeda Pharmaceutical by 56.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after buying an additional 1,292 shares during the period. Advisory Services Network LLC bought a new stake in Takeda Pharmaceutical in the third quarter valued at $74,000. Larson Financial Group LLC increased its position in Takeda Pharmaceutical by 43.7% during the 3rd quarter. Larson Financial Group LLC now owns 7,823 shares of the company’s stock valued at $115,000 after purchasing an additional 2,379 shares during the period. B. Riley Wealth Advisors Inc. purchased a new position in Takeda Pharmaceutical during the 2nd quarter valued at $174,000. Finally, BNP Paribas Financial Markets raised its holdings in Takeda Pharmaceutical by 1,652.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 11,845 shares of the company’s stock worth $183,000 after purchasing an additional 11,169 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TAK. Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Morgan Stanley started coverage on shares of Takeda Pharmaceutical in a research report on Tuesday, January 13th. They issued an “overweight” rating on the stock. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Saturday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Takeda Pharmaceutical currently has a consensus rating of “Hold”.

Takeda Pharmaceutical News Roundup

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Takeda raised FY‑2025 revenue guidance to $29.4 billion and issued EPS guidance of 3.160, above consensus revenue expectations — a clear near‑term positive for top‑line visibility and investor sentiment.
• Positive Sentiment: Q3 results beat expectations: EPS $0.95 vs. $0.55 consensus; management cited cost discipline, FX tailwinds and narrowing gap between Growth & Launch products and VYVANSE generic erosion—management is tightening OPEX and raising confidence in the full‑year outlook. Takeda Reports Third-Quarter FY2025 Results
• Neutral Sentiment: CEO Christophe Weber discussed succession planning and avoiding a ‘lame duck’ exit — governance and leadership continuity themes that reduce execution risk but are longer‑term in impact. Takeda’s Christophe Weber on avoiding a ‘lame duck’ succession
• Neutral Sentiment: Earnings‑call and transcript detail product performance, launch timing and cost actions — useful for modeling but not an immediate catalyst. Takeda Q3 FY2025 Earnings Call Transcript
• Negative Sentiment: Analyst downgrade from Buy to Hold after TAK hit 52‑week highs — valuation noted as less compelling and the lack of a clear Entyvio successor reduces near‑term upside; this can pressure sentiment and limit multiple expansion. Takeda Tests New Highs, But Struggles To Find Entyvio Successor
• Negative Sentiment: Legal exposure: an adverse jury outcome in an Actos-related case and active litigation motions (including efforts to move a Louisiana suit) represent potential liabilities and headline risk that can weigh on the stock. Takeda and Eli Lilly fall foul of jury in Actos Pharma company wants La. suit over stomach acid meds moved

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.